The Worse the MS, the More the Impact of Fatigue
A recent study helped researchers identify why it is that people with progressive MS in particular experience what they deemed “fatigue and dual-task impairment of walking and cognition.” Fatigue was judged on the Modified Fatigue Impact Scale (MFIS).
Using structural and functional MRI sequences, they observed a probable cause for this impairment.
It’s not just in our heads, as it were (though, of course, it is in our heads), that we find ourselves cognitively taxed when we’re fatigued. Both structural and functional frontal cortico-subcortical abnormalities were observed. (The cortex is the outer layer of the brain, and the subcortex comprises brain structures beneath the cortex.)
The worse a person’s MS was — judged by higher Expanded Disability Status Scale (EDSS) score, higher lesion load, and lower cortical volume (or more extensive brain atrophy) — the more significant the effect of fatigue on both the physical and cognitive symptoms of the disease.
It may seem obvious that the “worse” a person’s multiple sclerosis (the disease) is, the more something like fatigue would affect other symptoms. That there is another way to judge how “bad” the disease is by using these MRI techniques gives us proof of the physical relationship between how we feel and how we perform.
What About People With RRMS?
Although this study looked only at people with progressive or worsening forms of the disease, many people with relapsing-remitting MS might feel these results are their lived truths as well.
While brain atrophy can be seen in the earliest stages of MS and is a reliable predictor of future physical and cognitive disability, according to a paper published in Autoimmunity Highlights, those who have advanced to a progressive form of multiple sclerosis will likely have lost more brain volume over the course of their disease.
Study Highlights the Importance of Preserving Brain Volume
This research news is not a huge surprise for those of us living with MS, nor does it indicate any corrective action that might be undertaken to improve our situation. What it does do, however, is point again to the importance of maintaining as much brain volume as possible for as long as we can.
Reducing the rate of brain atrophy has only recently been seen as a critical endpoint for new MS disease-modifying drug trials.
If you are unsure of your rate of brain atrophy, ask your neurologist at your next appointment. If they don’t have an answer for you, make sure that it’s a marker that is assessed during your next MRI. Forewarned is forearmed when it comes to brain atrophy, and this research bears that out clearly.
Wishing you and your family the best of health.
Cheers,
Trevis
